Erasca Accelerates Pancreatic Cancer Study After Encouraging Monotherapy, Combination Results
Erasca reports strong Phase 1 tumor responses for ERAS-0015 and ERAS-4001 and accelerates its Phase 3 pancreatic cancer trial to early 2027.
Follow the latest Erasca, Inc. (ERAS) news and market headlines alongside the live ERAS price. Stay informed on what's moving ERAS.
Erasca reports strong Phase 1 tumor responses for ERAS-0015 and ERAS-4001 and accelerates its Phase 3 pancreatic cancer trial to early 2027.
Erasca announced positive Phase 1 data for ERAS-0015, a pan-RAS molecular glue, showing 44% confirmed ORR in 2L+ KRAS G12X PDAC and 69% in G12D/G12V PDAC, with 60% ORR in post-ICI/platinum NSCLC. The drug demonstrated favorable safety profile with mostly low-grade adverse events. The company plans to initiate potentially registration-enabling trials in lung cancer in H1 2027 and accelerated Phase 3 trial in pancreatic cancer in H1 2027. Early combination data with chemotherapy and immunotherapy showed promise, and ERAS-4001, a pan-KRAS inhibitor, showed preliminary antitumor activity.
Erasca and Bristol Myers Squibb announced a clinical trial collaboration to evaluate Erasca's pan-RAS molecular glue ERAS-0015 in combination with BMS's PRMT5 inhibitor navlimetostat for MTAP-deleted pancreatic cancer. BMS will sponsor the Phase 1/2 trial while Erasca supplies ERAS-0015. The combination targets the dependency created by co-occurring RAS mutations in nearly all MTAP-deleted pancreatic cancers.
Leerink Partners initiates coverage on Erasca (NASDAQ:ERAS) with a Outperform rating and announces Price Target of $35.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to ERAS, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.